Xtant Medical Holdings, Inc. (XTNT)
Largest Insider Buys in Sector
XTNT Stock Price History Chart
XTNT Stock Performance
About Xtant Medical Holdings, Inc.
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. Its biomaterial products include OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DBM Putty for use as a bone void filler …
Insider Activity of Xtant Medical Holdings, Inc.
Over the last 12 months, insiders at Xtant Medical Holdings, Inc. have bought $0 and sold $0 worth of Xtant Medical Holdings, Inc. stock.
On average, over the past 5 years, insiders at Xtant Medical Holdings, Inc. have bought $568,485 and sold $50,444 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 41,670 shares for transaction amount of $49,837 was made by Brandt Kevin D (Chief Commercial Officer) on 2023‑11‑17.
List of Insider Buy and Sell Transactions, Xtant Medical Holdings, Inc.
| 2023-11-17 | Chief Commercial Officer | 41,670 0.0341% | $1.20 | $49,837 | -25.73% | |||
| 2023-01-18 | Sale | Chief Financial Officer | 8,673 0.0082% | $0.61 | $5,283 | +55.93% | ||
| 2022-10-19 | Sale | President and CEO | 51,100 0.0471% | $0.62 | $31,820 | +9.68% | ||
| 2022-10-18 | Sale | President and CEO | 80,000 0.0763% | $0.68 | $54,008 | +4.62% | ||
| 2022-10-07 | director | 2.26M 1.4161% | $0.48 | $1.09M | -4.23% | |||
| 2022-08-15 | Sale | Chief Commercial Officer | 18,700 0.0162% | $0.49 | $9,172 | +26.92% | ||
| 2022-08-15 | Sale | Chief Financial Officer | 1,270 0.0011% | $0.48 | $605 | +26.92% | ||
| 2018-02-14 | 945,819 1.3083% | $7.20 | $6.81M | +15.06% | ||||
| 2018-02-14 | 945,819 1.3083% | $7.20 | $6.81M | +15.06% | ||||
| 2018-02-14 | 945,819 1.3083% | $7.20 | $6.81M | +15.06% | ||||
| 2016-05-09 | Chief Executive Officer | 5,000 0.0004% | $2.34 | $11,700 | -64.88% | |||
| 2015-12-03 | director | 2,300 0.0002% | $2.82 | $6,493 | -27.05% | |||
| 2015-12-01 | director | 1,000 <0.0001% | $2.85 | $2,850 | -28.07% | |||
| 2015-11-20 | EVP & Chief Scientific Officer | 2,000 0.0002% | $2.99 | $5,983 | -28.23% | |||
| 2015-11-20 | director | 4,976 0.0004% | $3.00 | $14,928 | -28.23% | |||
| 2015-11-19 | EVP & Chief Scientific Officer | 1,000 <0.0001% | $2.94 | $2,943 | -29.19% | |||
| 2015-11-19 | director | 24 <0.0001% | $2.90 | $70 | -29.19% | |||
| 2015-11-18 | EVP & Chief Scientific Officer | 1,000 <0.0001% | $2.86 | $2,862 | -27.24% | |||
| 2015-11-16 | Chief Executive Officer | 3,000 0.0002% | $2.80 | $8,400 | -20.45% | |||
| 2015-09-04 | Chief Executive Officer | 81,522 0.0062% | $3.68 | $300,001 | -33.42% |
Insider Historical Profitability
| ORBIMED ADVISORS LLC | 5890884 4.2378% | $0.36 | 1 | 0 | +15.06% | |
| Rizzo Matthew | 5890884 4.2378% | $0.36 | 1 | 0 | +15.06% | |
| Eggenberg Michael | 5890884 4.2378% | $0.36 | 1 | 0 | +15.06% | |
| Vizirgianakis Stavros G. | director | 5850716 4.2089% | $0.36 | 1 | 0 | <0.0001% |
| Kirschman David Louis | EVP & Chief Scientific Officer | 1701063 1.2237% | $0.36 | 3 | 0 | <0.0001% |
Institutional Investor Ownership
| OrbiMed | $85.54M | 56.13 | 73.11M | 0% | +$0 | 0.66 | |
| Altium Capital Management Lp | $8.95M | 5.87 | 7.65M | -4.73% | -$444,272.38 | 1.05 | |
| Nantahala Capital Management Llc | $4.68M | 3.07 | 4M | 0% | +$0 | 0.22 | |
| The Vanguard Group | $1.81M | 1.19 | 1.55M | +3.22% | +$56,533.23 | <0.0001 | |
| Renaissance Technologies | $893,000.00 | 0.59 | 763,310 | +3.02% | +$26,205.87 | <0.01 |